Efficacy of Semaglutide vs. Dulaglutide across Baseline HbA1c in SUSTAIN 7
Authors: PRATLEY RICHARD E. , FRIAS JUAN P. , KUMAR HARISH , PETRIE JOHN , NAVARRIA ANDREA , NIELSEN MORTEN ABILDLUND , SCHMIDT WOLFGANG E. 
Published: June 2018

Semaglutide, a new GLP-1 analog for T2D, showed significant and clinically meaningful HbA1c and body weight (BW) reductions across the SUSTAIN clinical trial program. This post-hoc analysis of the phase 3b SUSTAIN 7 trial evaluated once-weekly subcutaneous semaglutide 0.5 mg vs. dulaglutide 0.75 mg and semaglutide 1.0 mg vs. dulaglutide 1.5 mg by baseline (BL) HbA1c subgroups in subjects with T2D.

At week 40, improvements in HbA1c (Figure 1) and BW were similar or favored semaglutide vs. dulaglutide across subgroups (p-value for interaction: HbA1c, p=0.02; BW, p&gt;0.05); estimated treatment effects were similar or favored semaglutide. More subjects with BL HbA1c &gt;9% achieved HbA1c targets with semaglutide vs. dulaglutide (Figure 2).

Semaglutide was associated with similar or greater HbA1c and BW reductions vs. dulaglutide in all subjects regardless of BL HbA1c.

Disclosure

R.E. Pratley: Other Relationship; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eisai Inc., GlaxoSmithKline plc., Janssen Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc., Ligand Pharmaceuticals, Inc., Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk Inc., Pfizer Inc., Sanofi-Aventis, Takeda Development Center Americas, Inc. J.P. Frias: Research Support; Self; AbbVie Inc., Allergan, Amgen Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb Company. Consultant; Self; CeQur Corporation. Research Support; Self; Cirius Therapeutics, AstraZeneca, Calibra Medical, Elcelyx Therapeutics, Inc.. Consultant; Self; Elcelyx Therapeutics, Inc.. Research Support; Self; Eli Lilly and Company, Genentech, Inc., Ionis Pharmaceuticals, Inc., ICON plc., Janssen Pharmaceuticals, Inc.. Consultant; Self; Johnson & Johnson Diabetes Institute, LLC.. Research Support; Self; Lexicon Pharmaceuticals, Inc., Ligand Pharmaceuticals, Inc.. Consultant; Self; Ligand Pharmaceuticals, Inc.. Research Support; Self; Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Novo Nordisk Inc., Pfizer Inc., Sanofi. Consultant; Self; Sanofi. Speaker's Bureau; Self; Sanofi. Research Support; Self; Theracos, Inc. H. Kumar: Speaker's Bureau; Self; AstraZeneca, Novo Nordisk A/S. J. Petrie: Advisory Panel; Self; Novo Nordisk A/S. Other Relationship; Self; Boehringer Ingelheim GmbH. Speaker's Bureau; Self; Pfizer Inc.. Consultant; Self; Novo Nordisk A/S. Research Support; Self; Merck KGaA, Itamar Medical Ltd., Janssen Pharmaceuticals, Inc.. Other Relationship; Self; Diabetes UK, Applied Clinical Intelligence Ltd, Bayer AG, QuintilesIMS. A. Navarria: Employee; Self; Novo Nordisk A/S. M. Abildlund Nielsen: Employee; Self; Novo Nordisk A/S. Stock/Shareholder; Spouse/Partner; Novo Nordisk A/S. W.E. Schmidt: Speaker's Bureau; Self; Novo Nordisk A/S. Advisory Panel; Self; Novo Nordisk Inc.. Speaker's Bureau; Self; Berlin-Chemie AG, Berlin-Chemie AG, Merck Sharp & Dohme Corp., Boehringer Ingelheim GmbH. Advisory Panel; Self; Boehringer Ingelheim GmbH. Speaker's Bureau; Self; Eli Lilly and Company. Advisory Panel; Self; Eli Lilly and Company. Speaker's Bureau; Self; AstraZeneca.